{"name":"Kirilys Therapeutics Inc.","slug":"kirilys-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Kirilys Therapeutics Inc. is a biotechnology company focused on developing innovative treatments for unmet medical needs. The company's lead candidate, ASN004, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ASN004","genericName":"ASN004","slug":"asn004","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ASN004","genericName":"ASN004","slug":"asn004","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxORF9wd0RWVUthWk9TbWM1ZHA3dWRHNVJ6SVZNOEpYUG1FVGhyNVhZRlFlMmNCYy16X25sTm05YmN0QjJRR0hRUnp3U1h1aEtVTEtOQmZLMVotcnNBTlNIeFZuTXdWazY3MndLN3J2cllIOFdHRnRVbW5ZMm1HTUFCamdVSUxOTVd4bTdfM01KNml0d0RIYjQwU21qaHQyOXBiSjMteFhWa3FvZzlKZEdsWEozQ0NMVGpUcXZBT3ZmOFRydFlaMmZyVA?oc=5","date":"2024-07-26","type":"regulatory","source":"globaldata.com","summary":"Likelihood of Approval and Phase Transition Success Rate Model – KRLS-004 in Head And Neck Squamous Cell Carcinoma (HNSC) - globaldata.com","headline":"Likelihood of Approval and Phase Transition Success Rate Model – KRLS-004 in Head And Neck Squamous Cell Carcinoma (HNSC","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}